Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors  

作　　者：An-Jie Guo Qing-Yuan Deng Pan Dong Lian Zhou Lei Shi 

机构地区：[1]School of Life Sciences,Chongqing University,Chongqing 400044,China [2]Head and Neck Cancer Center,Chongqing University Cancer Hospital,Chongqing 400000,China

出　　处：《World Journal of Clinical Oncology》2024年第8期1002-1020,共19页世界临床肿瘤学杂志（英文版）

基　　金：Supported by The Fundamental Research Funds for the Central Universities,No.2019CDYGYB024;The National Natural Science Foundation of China,No.31300726;The Chongqing Primary and Middle School Innovation Talent Training Project,No.CY220113.

摘　　要：Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irAEs),significantly affecting the efficacy and survival rates of patients undergoing ICI therapy.While conventional hematological and imaging tests are adept at detecting organ-specific toxicities,distinguishing adverse reactions from those induced by viruses,bacteria,or immune diseases remains a formidable challenge.Consequently,there exists an urgent imperative for reliable biomarkers capable of accurately predicting or diagnosing irAEs.Thus,a thorough review of existing studies on irAEs biomarkers is indispensable.Our review commences by providing a succinct over-view of major irAEs,followed by a comprehensive summary of irAEs biomarkers across various dimensions.Furthermore,we delve into innovative methodologies such as machine learning,single-cell RNA sequencing,multiomics analysis,and gut microbiota profiling to identify novel,robust biomarkers that can facilitate precise irAEs diagnosis or prediction.Lastly,this review furnishes a concise exposition of irAEs mechanisms to augment understanding of irAEs prediction,diagnosis,and treatment strategies.

关 键 词：IMMUNOTHERAPY Immune checkpoint inhibitors Immune-related adverse events Biomarkers CANCERS 

分 类 号：R730.3[医药卫生—肿瘤]